NCT07210515: An ongoing trial by Ambros Therapeutics, Inc.
This trial is ongoing. It must report results 2 years, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07210515 |
|---|---|
| Title | A Randomized, Triple-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous AMBTX-01 (Neridronate) for Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-RISE) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 31, 2026 |
| Completion date | Dec. 31, 2027 |
| Required reporting date | Dec. 30, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 23, 2026 |
| Days late | None |